SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a focal point for intense community debate, with many traders holding polarized views on whether the asset represents a long-term opportunity or a declining trend. While some holders emphasize their conviction and anticipation of a potential market rally, a significant portion of the conversation is dominated by frustration over stagnant performance and skepticism regarding the project's long-term utility.

Chip

CHIP is gaining momentum as investors bet on USD.AI's role in financing physical AI infrastructure through GPU-backed lending. The community is actively debating the project's long-term utility against volatility and supply concerns, with many focusing on its potential as a governance layer for the growing AI compute market.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors debate the geopolitical ramifications of a new U.S.-Iran memorandum of understanding, alongside intense community discourse regarding the administration's recent foreign policy decisions. Participants are actively engaging in heated political debates, with many users fixating on the broader market impact of these developments and ongoing controversies surrounding the company's valuation.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is capturing investor attention as its multi-layered autonomous driving strategy gains traction, highlighted by a significant partnership with Lenovo to scale global deployment of autonomous vehicles and successful commercial robotaxi launches in markets like Dubai. Community sentiment is increasingly bullish, focusing on the company's competitive edge in L4-rated technology and the recent surge in institutional interest that suggests a potential shift toward stronger fundamental valuation.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending due to a co-development partnership with AI startup Midjourney, which highlights the company's semiconductor-based ultrasound-on-chip technology. Community members are actively debating the long-term potential of this strategic deal, with some long-term holders expressing high conviction while others caution against volatility and historical patterns of share offerings.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending as investors digest record-breaking revenue growth driven by sustained AI infrastructure demand, despite ongoing market caution regarding its reliance on advanced semiconductor manufacturing capacity. The community is actively debating the stock's long-term dominance as the essential foundry backbone for AI, weighed against persistent geopolitical risks and intense competition in next-generation chip packaging.

Anthropic

Anthropic is trending as it faces intense U.S. government scrutiny and forced restrictions on its most advanced AI models, Fable 5 and Mythos 5, due to national security concerns. The community is actively debating the company's IPO prospects, its competitive positioning against rivals like OpenAI and SpaceX, and the broader implications of rising AI regulation.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is attracting attention as it navigates a transition away from Humira, with investors closely watching its immunology growth and recent strategic M&A activity in the oncology and obesity spaces. Meanwhile, the community is actively debating the potential for acquisition-driven catalysts in the biotech sector, particularly centering on discussions around competitive drug readouts and the strategic value of late-stage pipeline assets.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is capturing community attention as traders weigh the impact of persistent supply disruptions in the Strait of Hormuz against ongoing uncertainty regarding a potential peace deal in the Iran-U.S. conflict. While investors are closely monitoring upcoming earnings for signals on production and capital allocation, the community remains divided between those betting on further supply-driven upside and those concerned about potential volatility if diplomatic tensions ease.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

The IBIT ETF is trending due to institutional options activity and intense community debate surrounding potential legislative catalysts like the Clarity Act. Traders are closely monitoring this price action as participants weigh speculative upside against broader market volatility and institutional distribution patterns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Lexeo Therapeutics Stock Gaining Monday?

Lexeo Therapeutics stock jumps as LX2006 pivotal trial moves forward, with SUNRISE-FA 2 enrollment set to begin in June 2026.read more...

Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-lexeo-therapeutics-inc-stock...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one...

Lexeo Therapeutics (NASDAQ:LXEO) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen cut Lexeo Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2%  - Should You Buy?

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Here's What Happened...

Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $312,950.00 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 55,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average...

Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 55,000 Shares of Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 55,000 shares of the firm's stock in a transaction dated Monday, April 6th. The shares were sold at an average...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are presently covering the stock, MarketBeat.com...

Lexeo Therapeutics (NASDAQ:LXEO) Issues Quarterly Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.03...

Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 23. (View Earnings Report at...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.29	--	--	N/A
Q1 '26	-$0.31	-$0.25	19.13%	BEAT
Q4 '25	-$0.31	-$0.27	14.23%	BEAT
Q3 '25	-$0.52	-$0.33	36.54%	BEAT
Q2 '25	-$0.68	-$0.60	11.68%	BEAT

LXEOLexeo Therapeutics Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest LXEO News